Information Provided By: 
Fly News Breaks for July 23, 2019
KRTX
Jul 23, 2019 | 06:29 EDT
Goldman Sachs analyst Salveen Richter started Karuna Therapeutics with a Buy rating and $34 price target. The analyst sees a favorable risk/reward setup since xanomeline has also demonstrated benefits in psychosis and cognition in two prior trials. He projects KarXT global peak sales of $4.4B.
News For KRTX From the Last 2 Days
KRTX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
